Key terms

About RDY

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services & Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services & Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research and development of differentiated formulations. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest RDY news

Yesterday 4:38am ET Dr Reddy’s Laboratories (RDY) Gets a Buy from Barclays May 03 9:58am ET Dr. Reddy’s Introduces Generic Doxycycline in U.S. Apr 30 3:27pm ET Dr. Reddy’s Faces Tax Demand, Plans Appeal Apr 25 7:57am ET Dr. Reddy’s Forges Nutraceuticals JV; Leadership Changes Apr 25 7:29am ET Nestlé and Dr. Reddy’s Forge Nutraceuticals JV Apr 23 2:57pm ET Dr. Reddy’s Announces Urgent Medication Recall Apr 22 6:58am ET Dr. Reddy’s Faces USFDA Hurdle for Biosimilar Apr 19 11:57am ET Dr. Reddy’s Introduces Innovative IBS Digital Care Plan Apr 19 8:27am ET Dr. Reddy’s Q4 and FY24 Financial Results Due Apr 18 11:57am ET Dr. Reddy’s Faces Tax Demand; Plans Appeal Apr 15 9:00pm ET Dr. Reddy’s Divests Venezuelan Subsidiary Stake Apr 05 10:27am ET Dr. Reddy’s Expands Heart Failure Therapy in India Mar 27 6:36am ET Dr. Reddy’s enters partnership with Sanofi to distribute vaccines in India Mar 22 8:28am ET Dr. Reddy’s Launches Novel Shock Treatment in India Mar 22 8:27am ET Dr. Reddy’s Upcoming Board Meeting & Trading Window Closure Mar 22 7:02am ET Dr. Reddy’s, Pharmazz enter licensing agreement to market Centhaquine Mar 19 7:28am ET Dr. Reddy’s Debuts Cancer Biosimilar in the UK Mar 11 8:36am ET Journey Medical presents data from Phase 1 trial of DFD-29

No recent press releases are available for RDY

RDY Financials

1-year income & revenue

Key terms

RDY Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

RDY Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms